<DOC>
	<DOCNO>NCT02328443</DOCNO>
	<brief_summary>Evaluation validation metabolic marker assessment CYP3A activity prediction drug-drug interaction Korean healthy subject .</brief_summary>
	<brief_title>Evaluation Validation Metabolic Markers Assessment CYP3A Activity Prediction DDI</brief_title>
	<detailed_description>Eligibility participation study determine demographic information , medical history , physical examination , electrocardiogram ( ECG ) clinical laboratory test within 4 week study drug administration . Subjects suitable study admit Clinical Trials Center , Seoul National University Hospital day dose , overnight-fasted 10 p.m. Day -1 . Urine collection schedule drug 12 hour 24 hour midazolam administration . Subjects dose study drug via intravenous around 9 a.m. Day 1 . Subjects perform scheduled procedure . In period 2 , Subjects admit Day 3-5 . Subjects perform scheduled period 2 ( Itraconazole co-administration phase , 2 time administration itraconazole 200 mg ) , period 3 ( rifampicin 150 mg co-administration phase ) procedure . Study participation terminate post-study visit ( Day 23~35 ) .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Age : Between 20 40 year age , inclusive Weight : within 1728 Body Mass Index ( BMI ) Subject reliable willing make available study period , willing follow study protocol , give write informed consent voluntarily History hypersensitive reaction medication ( midazolam , itraconazole , rifampicin ) History significant clinical illness need medical caution , include cardiovascular , immunologic , hematologic , neuropsychiatric , respiratory , gastrointestinal , hepatic , renal disease chronic disease History evidence drug abuse Use prescriptive medication , Korean traditional medication consider acceptable clinical investigator last 14 day period first dose , use medication consider acceptable clinical investigator last 7 day period first dose ( use medication consider acceptable investigator , patient include ) Participation clinical trial drug within 60 day prior participation study Judged inappropriate study investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CYP3A</keyword>
	<keyword>Metabolomics</keyword>
</DOC>